U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C26H35NO4
Molecular Weight 425.5604
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIPROTEVERINE

SMILES

CCOC1=C(OCC)C=C(CC2=NCCC3=C2C=C(OC(C)C)C(OC(C)C)=C3)C=C1

InChI

InChIKey=APMMVXSVJLZZRR-UHFFFAOYSA-N
InChI=1S/C26H35NO4/c1-7-28-23-10-9-19(14-24(23)29-8-2)13-22-21-16-26(31-18(5)6)25(30-17(3)4)15-20(21)11-12-27-22/h9-10,14-18H,7-8,11-13H2,1-6H3

HIDE SMILES / InChI

Molecular Formula C26H35NO4
Molecular Weight 425.5604
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Diproteverine is a calcium channel blocking agent. Diproteverine provoked a dose-dependent inhibition of LHRH-stimulated luteinizing hormone release. Diproteverine does not modify mean blood pressure. Diproteverine administered with and without pharmacologic autonomic blockade in the conscious dog causes dose-related depressant effects on sinus node function and atrioventricular conduction without producing significant vasodilatation. Diproteverine caused a redistribution of the available coronary blood flow, to the benefit of an ischemic area of the myocardium. The combination of the reduction in heart rate, to lower cardiac oxygen demand, with the beneficial action on coronary blood flow should result in diproteverinebeing particularly beneficial for the treatment of angina pectoris.

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
100 mg twice a day for 21 days
Route of Administration: Oral
Substance Class Chemical
Record UNII
8A5OIA91GT
Record Status Validated (UNII)
Record Version